Efficacy and Safety of 2 Doses of TEV-48125 Versus Placebo for the Prevention of Chronic Migraine

Study Title

Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine

Teva Identifier

TV48125-CNS-30049 | 2015-004549-23

ClinicalTrials.gov Identifier

NCT02621931

Study Status

Completed

Trial Condition(s)

Migraine

Interventions

Drug: Fremanezumab | Drug: Placebo

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Click for participation criteria and map of study locations

Key Participation Requirements

Gender

Female, Male

Age Range

18 Years to 70 Years

Trial Duration

March 22, 2016 - April 11, 2017

Phase

Phase 3

Study Type

Interventional